keyword
MENU ▼
Read by QxMD icon Read
search

melanoma Stage 3

keyword
https://www.readbyqxmd.com/read/28822576/pembrolizumab-versus-ipilimumab-for-advanced-melanoma-final-overall-survival-results-of-a-multicentre-randomised-open-label-phase-3-study-keynote-006
#1
Jacob Schachter, Antoni Ribas, Georgina V Long, Ana Arance, Jean-Jacques Grob, Laurent Mortier, Adil Daud, Matteo S Carlino, Catriona McNeil, Michal Lotem, James Larkin, Paul Lorigan, Bart Neyns, Christian Blank, Teresa M Petrella, Omid Hamid, Honghong Zhou, Scot Ebbinghaus, Nageatte Ibrahim, Caroline Robert
BACKGROUND: Interim analyses of the phase 3 KEYNOTE-006 study showed superior overall and progression-free survival of pembrolizumab versus ipilimumab in patients with advanced melanoma. We present the final protocol-specified survival analysis. METHODS: In this multicentre, open-label, randomised, phase 3 trial, we recruited patients from 87 academic institutions, hospitals, and cancer centres in 16 countries (Australia, Austria, Belgium, Canada, Chile, Colombia, France, Germany, Israel, Netherlands, New Zealand, Norway, Spain, Sweden, UK, and USA)...
August 16, 2017: Lancet
https://www.readbyqxmd.com/read/28820834/super-thin-scip-flap-for-reconstruction-of-subungual-melanoma-aesthetic-functional-surgery
#2
Kyeong-Tae Lee, Bo Young Park, Eun-Ji Kim, Jung-Han Kim, Kee-Taek Jang, Sang-Hee Choi, Dong-Youn Lee, Goo-Hyun Mun
BACKGROUND: This study aimed to use a super-thin, free superficial circumflex iliac artery perforator (SCIP) flap in the functional surgery for treating subungual melanoma and to evaluate its outcomes. METHODS: Forty-one patients with primary subungual melanoma of ≤ 2-mm thickness who were treated with functional surgery were prospectively enrolled. Following oncologic resection, a thin SCIP flap was harvested along the trans-superficial fat layer and transferred to the defect with further thinning by primary defatting...
August 8, 2017: Plastic and Reconstructive Surgery
https://www.readbyqxmd.com/read/28816150/phase-1-study-of-ipilimumab-combined-with-whole-brain-radiation-therapy-or-radiosurgery-for-melanoma-patients-with-brain-metastases
#3
MULTICENTER STUDY
Noelle L Williams, Evan J Wuthrick, Hyun Kim, Joshua D Palmer, Shivank Garg, Harriet Eldredge-Hindy, Constantine Daskalakis, Kendra J Feeney, Michael J Mastrangelo, Lyndon J Kim, Takami Sato, Kari L Kendra, Thomas Olencki, David A Liebner, Christopher J Farrell, James J Evans, Kevin D Judy, David W Andrews, Adam P Dicker, Maria Werner-Wasik, Wenyin Shi
PURPOSE: We performed a phase 1 study to determine the maximum tolerable dose and safety of ipilimumab with stereotactic radiosurgery (SRS) or whole brain radiation therapy (WBRT) in patients with brain metastases from melanoma. METHODS AND MATERIALS: Based on the intracranial disease burden, patients underwent WBRT (arm A) or SRS (arm B). The ipilimumab starting dose was 3 mg/kg every 3 weeks, starting on day 3 of WBRT or 2 days after SRS. The ipilimumab dose was escalated to 10 mg/kg using a 2-stage, 3+3 design...
September 1, 2017: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/28810986/cancer-incidence-among-patients-of-the-u-s-veterans-affairs-health-care-system-2010-update
#4
Leah L Zullig, Kellie J Sims, Rebecca McNeil, Christina D Williams, George L Jackson, Dawn Provenzale, Michael J Kelley
INTRODUCTION: Nearly 50,000 incident cancer cases are reported in Veterans Affairs (VA) Central Cancer Registry (VACCR) annually. This article provides an updated report of cancer incidence recorded in VACCR. MATERIALS AND METHODS: Data were obtained from VACCR for incident cancers diagnosed in the VA health care system, focusing on 2010 data. Cancer incidence among VA patients is described by anatomical site, sex, race, stage, and geographic location, and was compared to the general U...
July 2017: Military Medicine
https://www.readbyqxmd.com/read/28806256/recurrent-malignant-melanoma-detected-on-18f-fluciclovine-pet-ct-imaging-for-prostate-cancer
#5
Eugene J Teoh, Maria T Tsakok, Kevin M Bradley, Katherine Hyde, Manil Subesinghe, Fergus V Gleeson
A 66-year-old man presented with biochemical recurrence of prostate cancer and underwent F-fluciclovine PET/CT to detect sites of recurrence. He had a history of resected truncal stage IIIC malignant melanoma, with bilateral axillary node involvement on sentinel node biopsy, in complete remission for 3 years. F-fluciclovine PET/CT demonstrated an incidental fluciclovine-avid right axillary node (SUVmax = 4.3). Diagnostic sampling confirmed recurrent malignant melanoma.
August 12, 2017: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/28799187/safety-evaluation-of-combination-carboplatin-and-toceranib-phosphate-palladia-in-tumour-bearing-dogs-a-phase-i-dose-finding-study
#6
R M Wouda, S E Hocker, M L Higginbotham
Combining conventional cytotoxic maximum tolerated dose (MTD) chemotherapy with low-dose metronomic and/or anti-angiogenic agents is a exciting area of oncologic research. The objective of this study was to establish the MTD, safety and adverse event (AE) profile of 1 such drug combination. This prospective phase I dose-finding clinical trial assumed an open-label 3 + 3 cohort design. Client-owned dogs with 1 or more cytologically and/or histologically confirmed and macroscopically measurable, naive or recurrent, malignant tumours, were enrolled...
August 10, 2017: Veterinary and Comparative Oncology
https://www.readbyqxmd.com/read/28797232/prognostic-significance-of-braf-and-nras-mutations-in-melanoma-a-german-study-from-routine-care
#7
Markus V Heppt, Timo Siepmann, Jutta Engel, Gabriele Schubert-Fritschle, Renate Eckel, Laura Mirlach, Thomas Kirchner, Andreas Jung, Anja Gesierich, Thomas Ruzicka, Michael J Flaig, Carola Berking
BACKGROUND: Hotspot mutations of the oncogenes BRAF and NRAS are the most common genetic alterations in cutaneous melanoma. Specific inhibitors of BRAF and MEK have shown significant survival benefits in large phase III trials. However, the prognostic significance of BRAF and NRAS mutations outside of clinical trials remains unclear. METHODS: The mutational status of BRAF (exon 15) and NRAS (exon 2 and 3) was determined in melanoma samples of 217 patients with pyrosequencing and Sanger sequencing...
August 10, 2017: BMC Cancer
https://www.readbyqxmd.com/read/28756584/estimated-healthcare-costs-of-melanoma-in-australia-over-3%C3%A2-years-post-diagnosis
#8
Thomas M Elliott, David C Whiteman, Catherine M Olsen, Louisa G Gordon
BACKGROUND: Skin cancer exerts a large and growing burden on health systems. With new pharmacotherapies for metastatic melanoma now available, a contemporary understanding of the cost burden of melanoma control is warranted. OBJECTIVE: To comprehensively assess the healthcare costs of malignant melanoma diagnosis and treatment in Australia, over 3 years after diagnosis. METHODS: We developed a decision-analytic model and micro-costing method to estimate the mean cost per patient for melanoma, incorporating all diagnostic and treatment modalities used in Australia (2017 AU$)...
July 29, 2017: Applied Health Economics and Health Policy
https://www.readbyqxmd.com/read/28750139/is-mitotic-rate-still-useful-in-the-management-of-patients-with-thin-melanoma
#9
Antonio Tejera-Vaquerizo, Gladys Pérez-Cabello, Lorena Marínez-Leborans, Elena Gallego, Vicente Oliver-Martínez, Paula Martín-Cuevas, Salvador Arias-Santiago, José Aneiros-González, Enrique Herrera-Acosta, Victor Traves, Enrique Herrera-Ceballos, Eduardo Nagore
BACKGROUND: T1 melanoma substaging was recently modified by the American Joint Committee on Cancer (AJCC). Although sentinel lymph node (SLN) positivity is the most important prognostic factor in melanoma, there is a lack of consensus on whether SLN biopsy should be performed in patients with thin melanoma (≤1 mm). OBJECTIVE: The main aim of this study was to investigate predictors of SLN positivity in patients with thin melanoma, with a special emphasis on mitotic rate...
July 27, 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/28746718/association-of-incident-amelanotic-melanoma-with-phenotypic-characteristics-mc1r-status-and-prior-amelanotic-melanoma
#10
Steven Vernali, Weston T Waxweiler, Patrick M Dillon, Peter A Kanetsky, Irene Orlow, Li Luo, Klaus J Busam, Anne Kricker, Bruce K Armstrong, Hoda Anton-Culver, Stephen B Gruber, Richard P Gallagher, Roberto Zanetti, Stefano Rosso, Lidia Sacchetto, Terence Dwyer, Anne E Cust, David W Ollila, Colin B Begg, Marianne Berwick, Nancy E Thomas
Importance: We previously reported that survival is poorer from histopathologically amelanotic than pigmented melanoma because of more advanced stage at diagnosis. Identifying patients at risk of amelanotic melanoma might enable earlier diagnosis and improved survival; however, the phenotypic characteristics and underlying genetics associated with amelanotic melanoma are unknown. Objective: To determine whether phenotypic characteristics, carriage of MC1R variants, and history of amelanotic melanoma are associated with histopathologically amelanotic melanoma...
July 26, 2017: JAMA Dermatology
https://www.readbyqxmd.com/read/28737620/sarcoidosis-following-anti-pd-1-and-anti-ctla-4-therapy-for-metastatic-melanoma
#11
Swathi B Reddy, Jennifer D Possick, Harriet M Kluger, Anjela Galan, Dale Han
Immune checkpoint inhibitors represent the newest treatment for stage IV melanoma. These agents are generally well tolerated, however severe immune-related adverse effects have been noted in a small, but clinically significant percentage of patients. Specifically, sarcoidosis is a known potential complication following anti-CTLA-4 therapy. We present 2 cases of pulmonary and cutaneous sarcoidosis developing in patients with stage IV melanoma. Both patients were treated with ipilimumab and anti-PD-1 therapy, and both experienced good oncologic responses to treatment; neither had evidence of preexisting sarcoidosis...
July 21, 2017: Journal of Immunotherapy
https://www.readbyqxmd.com/read/28736522/gliotoxin-targets-nuclear-notch2-in-human-solid-tumor-derived-cell-lines-in-vitro-and-inhibits-melanoma-growth-in-xenograft-mouse-model
#12
Rainer Hubmann, Wolfgang Sieghart, Susanne Schnabl, Mohammad Araghi, Martin Hilgarth, Marlies Reiter, Dita Demirtas, Peter Valent, Christoph Zielinski, Ulrich Jäger, Medhat Shehata
Deregulation of NOTCH2 signaling is implicated in a wide variety of human neoplasias. The current concept of targeting NOTCH is based on using gamma secretase inhibitors (GSI) to regulate the release of the active NOTCH intracellular domain. However, the clinical outcome of GSI remains unsatisfactory. Therefore we analyzed human solid tumor derived cell lines for their nuclear NOTCH activity and evaluated the therapeutic potential of the NOTCH2 transactivation inhibitor gliotoxin in comparison to the representative GSI DAPT...
2017: Frontiers in Pharmacology
https://www.readbyqxmd.com/read/28724122/association-between-patient-age-and-lymph-node-positivity-in-thin-melanoma
#13
Andrew J Sinnamon, Madalyn G Neuwirth, Pratyusha Yalamanchi, Phyllis Gimotty, David E Elder, Xiaowei Xu, Rachel R Kelz, Robert E Roses, Emily Y Chu, Michael E Ming, Douglas L Fraker, Giorgos C Karakousis
Importance: More than half of all new melanoma diagnoses present as clinically localized T1 melanoma, yet sentinel lymph node biopsy (SLNB) is controversial in this population given the overall low yield. Guidelines for SLNB have focused on pathologic factors, but patient factors, such as age, are not routinely considered. Objectives: To identify indicators of lymph node (LN) metastasis in thin melanoma in a large, generalizable data set and to evaluate the association between patient age and LN positivity...
July 19, 2017: JAMA Dermatology
https://www.readbyqxmd.com/read/28723726/impact-of-socioeconomic-status-and-district-of-residence-on-cutaneous-malignant-melanoma-prognosis-a-survival-study-on-incident-cases-between-1991-and-2011-in-the-province-of-ferrara-northern-italy
#14
Alessandro Borghi, Monica Corazza, Annarosa Virgili, Anna G Lambertini, Nicola Caranci, Barbara Pacelli, Paolo Carcoforo, Stefano Ferretti
The aim of this study was to analyse the impact of socioeconomic status (SES) on the prognosis of patients with invasive malignant melanoma (MM) incident from 1991 to 2011 in the province of Ferrara, northern Italy. A total of 750 patients provided by the Area Vasta Emilia Centrale Cancer Registry were included in this retrospective cohort study. Prognosis was analysed in terms of overall survival and specific survival. The study determinants were the patients' SES and district of residence. The confounding effect of sex, age, period and TNM stage at diagnosis was evaluated...
July 18, 2017: Melanoma Research
https://www.readbyqxmd.com/read/28710916/systemic-immune-inflammation-index-and-circulating-t-cell-immune-index-predict-outcomes-in-high-risk-acral-melanoma-patients-treated-with-high-dose-interferon
#15
Jiayi Yu, Xiaowen Wu, Huan Yu, Siming Li, LiLi Mao, Zhihong Chi, Lu Si, Xinan Sheng, Chuanliang Cui, Jie Dai, Meng Ma, Huan Tang, Tianxiao Xu, Junya Yan, Yan Kong, Jun Guo
High-dose interferon alfa-2b (IFN-α-2b) improves the survival of patients with high-risk melanoma. We aimed to identify baseline peripheral blood biomarkers to predict the outcome of acral melanoma patients treated with IFN-α-2b. Pretreatment baseline parameters and clinical data were assessed in 226 patients with acral melanoma. Relapse-free survival (RFS) and overall survival (OS) were assessed using the Kaplan-Meier method, and multivariate Cox regression analyses were applied after adjusting for stage, lactate dehydrogenase (LDH), and ulceration...
July 12, 2017: Translational Oncology
https://www.readbyqxmd.com/read/28698757/new-safety-margins-for-melanoma-surgery-nice-possibility-for-drinking-of-just-that-cup-of-coffee
#16
Georgi Tchernev, Anastasiya Atanasova Chokoeva
BACKGROUND: The American Joint Committee on Cancer (AJCC's) skin melanoma surgical treatment recommendations from 2011 are characterised by a prima facie "freedom of choice" regarding how extensive should be the excisions for melanomas with tumour thickness up to 2 mm and melanoma in situ. It is unclear why the recommended surgical security margins vary between 0.5 and 1 cm for melanoma in situ, whereas for melanomas with a tumour thickness of up to 1.99 mm, the range of variation is also between 1 and 2 cm, without specifying when the surgical field should be broader and, narrower, accordingly...
June 15, 2017: Open Access Macedonian Journal of Medical Sciences
https://www.readbyqxmd.com/read/28692949/adjuvant-interferon-%C3%AE-for-the-treatment-of-high-risk-melanoma-an-individual-patient-data-meta-analysis
#17
REVIEW
Natalie J Ives, Stefan Suciu, Alexander M M Eggermont, John Kirkwood, Paul Lorigan, Svetomir N Markovic, Claus Garbe, Keith Wheatley
BACKGROUND: Many randomised trials assessing interferon-α (IFN-α) as adjuvant therapy for high-risk malignant melanoma have been undertaken. To better assess the role of IFN-α, an individual patient data (IPD) meta-analysis of these trials was undertaken. METHODS: IPD was sought from all randomised trials of adjuvant IFN-α versus no IFN-α for high-risk melanoma. Primary outcomes were event-free survival (EFS) and overall survival (OS). Standard methods for quantitative IPD meta-analysis were used...
July 7, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28685276/post-trimodality-expression-levels-of-metadherin-mtdh-as-a-prognostic-biomarker-for-esophageal-adenocarcinoma-patients
#18
Dilsa Mizrak Kaya, Xiaochuan Dong, Graciela M Nogueras-González, Yan Xu, Jeannelyn S Estrella, Kazuto Harada, Anthony Lopez, Fatemeh G Amlashi, Wayne L Hofstetter, Dipen M Maru, Quynh-Nhu Nguyen, Jeffrey H Lee, Brian Weston, Manoop S Bhutani, Jeremy J Erasmus, Irene Thomas, Jane E Rogers, Shumei Song, Jaffer A Ajani
Resectable esophageal adenocarcinoma (EAC) patients often receive chemoradiation followed by surgery. However, most patients experience recurrences. Overexpression of MTDH, an oncoprotein with multiple functions, has been found to be associated with poor prognosis in breast cancer, glioblastoma, melanoma and various gastrointestinal malignancies, but not in EAC. We sought to establish its role in resistant EAC (post-treatment residual EAC). MTDH was assessed by immunohistochemistry in resected EAC, and results were correlated with clinical outcomes...
August 2017: Medical Oncology
https://www.readbyqxmd.com/read/28673886/newly-diagnosed-sellar-tumors-in-cancer-patients-a-diagnostic-challenge-and-management-dilemma
#19
Carlos R Goulart, Smita Upadhyay, Leo F S Ditzel Filho, Andre Beer-Furlan, Ricardo L Carrau, Luciano M Prevedello, Daniel M Prevedello
OBJECTIVE: The use of PET CT for staging in cancer patients and the widespread use of MRI led to an increased incidence of incidental sellar mass detection. The imaging findings can be suggestive of a benign pituitary tumor but metastasis can never be completely ruled out with non-invasive work-up. Appropriate diagnosis of these sellar masses is critical as the treatment paradigm might change in the presence of a pituitary metastasis. Moreover, definitive tissue diagnosis might prevent unnecessary radiotherapy to the skull base or even the need for systemic treatment when benign pituitary disease is confirmed...
June 30, 2017: World Neurosurgery
https://www.readbyqxmd.com/read/28669590/tranexamic-acid-inhibits-melanogenesis-by-activating-the-autophagy-system-in-cultured-melanoma-cells
#20
Yeong Hee Cho, Jung Eun Park, Do Sung Lim, Jung Sup Lee
BACKGROUND: As interest in skin beauty increases, the development of new skin whitening agents has attracted substantial attention; however, the action mechanism of the agents developed so far remains largely unknown. Tranexamic acid (TXA) is commonly being used to reduce melanin synthesis in patients with melasma and also used as a raw material for functional whitening cosmetics, although its action mechanism is poorly understood. Autophagy has been well known to be essential for tissue homeostasis, adaptation to starvation, and removal of dysfunctional organelles or pathogens...
June 7, 2017: Journal of Dermatological Science
keyword
keyword
62301
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"